Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Q-Actin is a proprietary natural product extract derived from cucumber (*Cucumis sativus*), developed by Phytoquest. It is standardized for its content of idoBR1, a bioactive iminosugar that acts as a glycosidase inhibitor. This mechanism of action is associated with the modulation of inflammatory pathways, specifically the reduction of pro-inflammatory cytokines such as TNF-alpha. Q-Actin is primarily marketed as a dietary supplement for joint health, with clinical evidence supporting its efficacy in reducing pain and improving physical function in patients with osteoarthritis. Additionally, Phytoquest is investigating the extract's potential applications in muscle recovery, sports performance, and neuroinflammation-related brain health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Q-Actin.